Tenofovir alafenamide and tenofovir disoproxil fumarate reduce incidence of hepatocellular carcinoma in patients with chronic hepatitis B

Antiviral therapy; Incidence

Detalhes bibliográficos
Autores: Lim, Young-Suk, Ahn, Sang-Hoon, Seto, Wai-Kay, Ning, Qin, Agarwal, Kosh, Chan, Henry Lik Yuen, Buti Ferret, Maria
Tipo de documento: artigo
Estado:Versão publicada
Data de publicação:2023
País:España
Recursos:Varias* (Consorci de Biblioteques Universitáries de Catalunya, Centre de Serveis Científics i Acadèmics de Catalunya)
Repositório:Recercat. Dipósit de la Recerca de Catalunya
OAI Identifier:oai:recercat.cat:11351/10413
Acesso em linha:https://hdl.handle.net/11351/10413
http://hdl.handle.net/11351/10413
Access Level:Acceso aberto
Palavra-chave:Medicaments antivírics - Ús terapèutic
Hepatitis B
Fetge - Càncer - Tractament
DISEASES::Neoplasms::Neoplasms::Neoplasms by Site::Digestive System Neoplasms::Liver Neoplasms::Carcinoma, Hepatocellular
Other subheadings::Other subheadings::Other subheadings::/drug therapy
DISEASES::Digestive System Diseases::Liver Diseases::Hepatitis::Hepatitis, Chronic::Digestive System Diseases::Liver Diseases::Hepatitis::Hepatitis B, Chronic
CHEMICALS AND DRUGS::Chemical Actions and Uses::Pharmacologic Actions::Therapeutic Uses::Anti-Infective Agents::Antiviral Agents
Other subheadings::Other subheadings::/therapeutic use
ENFERMEDADES::neoplasias::neoplasias::neoplasias por localización::neoplasias del sistema digestivo::neoplasias hepáticas::carcinoma hepatocelular
Otros calificadores::Otros calificadores::Otros calificadores::/farmacoterapia
ENFERMEDADES::enfermedades del sistema digestivo::enfermedades hepáticas::hepatitis::hepatitis crónica::enfermedades del sistema digestivo::enfermedades hepáticas::hepatitis::hepatitis B crónica
COMPUESTOS QUÍMICOS Y DROGAS::acciones y usos químicos::acciones farmacológicas::usos terapéuticos::antiinfecciosos::antivíricos
Otros calificadores::Otros calificadores::/uso terapéutico
id ES_49ed7ba94e75b226492a3de7e9abcf2e
oai_identifier_str oai:recercat.cat:11351/10413
network_acronym_str ES
network_name_str España
repository_id_str
dc.title.none.fl_str_mv Tenofovir alafenamide and tenofovir disoproxil fumarate reduce incidence of hepatocellular carcinoma in patients with chronic hepatitis B
title Tenofovir alafenamide and tenofovir disoproxil fumarate reduce incidence of hepatocellular carcinoma in patients with chronic hepatitis B
spellingShingle Tenofovir alafenamide and tenofovir disoproxil fumarate reduce incidence of hepatocellular carcinoma in patients with chronic hepatitis B
Lim, Young-Suk
Medicaments antivírics - Ús terapèutic
Hepatitis B
Fetge - Càncer - Tractament
DISEASES::Neoplasms::Neoplasms::Neoplasms by Site::Digestive System Neoplasms::Liver Neoplasms::Carcinoma, Hepatocellular
Other subheadings::Other subheadings::Other subheadings::/drug therapy
DISEASES::Digestive System Diseases::Liver Diseases::Hepatitis::Hepatitis, Chronic::Digestive System Diseases::Liver Diseases::Hepatitis::Hepatitis B, Chronic
CHEMICALS AND DRUGS::Chemical Actions and Uses::Pharmacologic Actions::Therapeutic Uses::Anti-Infective Agents::Antiviral Agents
Other subheadings::Other subheadings::/therapeutic use
ENFERMEDADES::neoplasias::neoplasias::neoplasias por localización::neoplasias del sistema digestivo::neoplasias hepáticas::carcinoma hepatocelular
Otros calificadores::Otros calificadores::Otros calificadores::/farmacoterapia
ENFERMEDADES::enfermedades del sistema digestivo::enfermedades hepáticas::hepatitis::hepatitis crónica::enfermedades del sistema digestivo::enfermedades hepáticas::hepatitis::hepatitis B crónica
COMPUESTOS QUÍMICOS Y DROGAS::acciones y usos químicos::acciones farmacológicas::usos terapéuticos::antiinfecciosos::antivíricos
Otros calificadores::Otros calificadores::/uso terapéutico
title_short Tenofovir alafenamide and tenofovir disoproxil fumarate reduce incidence of hepatocellular carcinoma in patients with chronic hepatitis B
title_full Tenofovir alafenamide and tenofovir disoproxil fumarate reduce incidence of hepatocellular carcinoma in patients with chronic hepatitis B
title_fullStr Tenofovir alafenamide and tenofovir disoproxil fumarate reduce incidence of hepatocellular carcinoma in patients with chronic hepatitis B
title_full_unstemmed Tenofovir alafenamide and tenofovir disoproxil fumarate reduce incidence of hepatocellular carcinoma in patients with chronic hepatitis B
title_sort Tenofovir alafenamide and tenofovir disoproxil fumarate reduce incidence of hepatocellular carcinoma in patients with chronic hepatitis B
dc.creator.none.fl_str_mv Lim, Young-Suk
Ahn, Sang-Hoon
Seto, Wai-Kay
Ning, Qin
Agarwal, Kosh
Chan, Henry Lik Yuen
Buti Ferret, Maria
author Lim, Young-Suk
author_facet Lim, Young-Suk
Ahn, Sang-Hoon
Seto, Wai-Kay
Ning, Qin
Agarwal, Kosh
Chan, Henry Lik Yuen
Buti Ferret, Maria
author_role author
author2 Ahn, Sang-Hoon
Seto, Wai-Kay
Ning, Qin
Agarwal, Kosh
Chan, Henry Lik Yuen
Buti Ferret, Maria
author2_role author
author
author
author
author
author
dc.contributor.none.fl_str_mv Institut Català de la Salut
[Lim YS] Asan Medical Center, University of Ulsan College of Medicine, Seoul, South Korea. [Chan HLY] The Chinese University of Hong Kong, Hong Kong. [Ahn SH] Yonsei University College of Medicine, Seoul, Republic of Korea. [Seto WK] University of Hong Kong, Hong Kong. [Ning Q] Tongji Hospital, Tongji Medical College, Wuhan, China. [Agarwal K] Institute of Liver Studies, Kings College Hospital, United Kingdom. [Buti M] Vall d’Hebron Hospital Universitari, Barcelona, Spain. CIBEREHD del Instituto Carlos III, Barcelona, Spain
Vall d'Hebron Barcelona Hospital Campus
dc.subject.none.fl_str_mv Medicaments antivírics - Ús terapèutic
Hepatitis B
Fetge - Càncer - Tractament
DISEASES::Neoplasms::Neoplasms::Neoplasms by Site::Digestive System Neoplasms::Liver Neoplasms::Carcinoma, Hepatocellular
Other subheadings::Other subheadings::Other subheadings::/drug therapy
DISEASES::Digestive System Diseases::Liver Diseases::Hepatitis::Hepatitis, Chronic::Digestive System Diseases::Liver Diseases::Hepatitis::Hepatitis B, Chronic
CHEMICALS AND DRUGS::Chemical Actions and Uses::Pharmacologic Actions::Therapeutic Uses::Anti-Infective Agents::Antiviral Agents
Other subheadings::Other subheadings::/therapeutic use
ENFERMEDADES::neoplasias::neoplasias::neoplasias por localización::neoplasias del sistema digestivo::neoplasias hepáticas::carcinoma hepatocelular
Otros calificadores::Otros calificadores::Otros calificadores::/farmacoterapia
ENFERMEDADES::enfermedades del sistema digestivo::enfermedades hepáticas::hepatitis::hepatitis crónica::enfermedades del sistema digestivo::enfermedades hepáticas::hepatitis::hepatitis B crónica
COMPUESTOS QUÍMICOS Y DROGAS::acciones y usos químicos::acciones farmacológicas::usos terapéuticos::antiinfecciosos::antivíricos
Otros calificadores::Otros calificadores::/uso terapéutico
topic Medicaments antivírics - Ús terapèutic
Hepatitis B
Fetge - Càncer - Tractament
DISEASES::Neoplasms::Neoplasms::Neoplasms by Site::Digestive System Neoplasms::Liver Neoplasms::Carcinoma, Hepatocellular
Other subheadings::Other subheadings::Other subheadings::/drug therapy
DISEASES::Digestive System Diseases::Liver Diseases::Hepatitis::Hepatitis, Chronic::Digestive System Diseases::Liver Diseases::Hepatitis::Hepatitis B, Chronic
CHEMICALS AND DRUGS::Chemical Actions and Uses::Pharmacologic Actions::Therapeutic Uses::Anti-Infective Agents::Antiviral Agents
Other subheadings::Other subheadings::/therapeutic use
ENFERMEDADES::neoplasias::neoplasias::neoplasias por localización::neoplasias del sistema digestivo::neoplasias hepáticas::carcinoma hepatocelular
Otros calificadores::Otros calificadores::Otros calificadores::/farmacoterapia
ENFERMEDADES::enfermedades del sistema digestivo::enfermedades hepáticas::hepatitis::hepatitis crónica::enfermedades del sistema digestivo::enfermedades hepáticas::hepatitis::hepatitis B crónica
COMPUESTOS QUÍMICOS Y DROGAS::acciones y usos químicos::acciones farmacológicas::usos terapéuticos::antiinfecciosos::antivíricos
Otros calificadores::Otros calificadores::/uso terapéutico
description Antiviral therapy; Incidence
publishDate 2023
dc.date.none.fl_str_mv 2023
2023
2023
dc.type.none.fl_str_mv info:eu-repo/semantics/article
info:eu-repo/semantics/publishedVersion
format article
status_str publishedVersion
dc.identifier.none.fl_str_mv https://hdl.handle.net/11351/10413
http://hdl.handle.net/11351/10413
url https://hdl.handle.net/11351/10413
http://hdl.handle.net/11351/10413
dc.language.none.fl_str_mv Inglés
language_invalid_str_mv Inglés
dc.relation.none.fl_str_mv JHEP Reports;5(10)
https://doi.org/10.1016/j.jhepr.2023.100847
dc.rights.none.fl_str_mv Attribution-NonCommercial-NoDerivatives 4.0 International
http://creativecommons.org/licenses/by-nc-nd/4.0/
info:eu-repo/semantics/openAccess
rights_invalid_str_mv Attribution-NonCommercial-NoDerivatives 4.0 International
http://creativecommons.org/licenses/by-nc-nd/4.0/
eu_rights_str_mv openAccess
dc.format.none.fl_str_mv application/pdf
application/pdf
application/pdf
dc.publisher.none.fl_str_mv Elsevier
publisher.none.fl_str_mv Elsevier
dc.source.none.fl_str_mv Scientia
reponame:Recercat. Dipósit de la Recerca de Catalunya
instname:Varias* (Consorci de Biblioteques Universitáries de Catalunya, Centre de Serveis Científics i Acadèmics de Catalunya)
instname_str Varias* (Consorci de Biblioteques Universitáries de Catalunya, Centre de Serveis Científics i Acadèmics de Catalunya)
reponame_str Recercat. Dipósit de la Recerca de Catalunya
collection Recercat. Dipósit de la Recerca de Catalunya
repository.name.fl_str_mv
repository.mail.fl_str_mv
_version_ 1869407454102552576
spelling Tenofovir alafenamide and tenofovir disoproxil fumarate reduce incidence of hepatocellular carcinoma in patients with chronic hepatitis BLim, Young-SukAhn, Sang-HoonSeto, Wai-KayNing, QinAgarwal, KoshChan, Henry Lik YuenButi Ferret, MariaMedicaments antivírics - Ús terapèuticHepatitis BFetge - Càncer - TractamentDISEASES::Neoplasms::Neoplasms::Neoplasms by Site::Digestive System Neoplasms::Liver Neoplasms::Carcinoma, HepatocellularOther subheadings::Other subheadings::Other subheadings::/drug therapyDISEASES::Digestive System Diseases::Liver Diseases::Hepatitis::Hepatitis, Chronic::Digestive System Diseases::Liver Diseases::Hepatitis::Hepatitis B, ChronicCHEMICALS AND DRUGS::Chemical Actions and Uses::Pharmacologic Actions::Therapeutic Uses::Anti-Infective Agents::Antiviral AgentsOther subheadings::Other subheadings::/therapeutic useENFERMEDADES::neoplasias::neoplasias::neoplasias por localización::neoplasias del sistema digestivo::neoplasias hepáticas::carcinoma hepatocelularOtros calificadores::Otros calificadores::Otros calificadores::/farmacoterapiaENFERMEDADES::enfermedades del sistema digestivo::enfermedades hepáticas::hepatitis::hepatitis crónica::enfermedades del sistema digestivo::enfermedades hepáticas::hepatitis::hepatitis B crónicaCOMPUESTOS QUÍMICOS Y DROGAS::acciones y usos químicos::acciones farmacológicas::usos terapéuticos::antiinfecciosos::antivíricosOtros calificadores::Otros calificadores::/uso terapéuticoAntiviral therapy; IncidenceTerapia antiviral; IncidenciaTeràpia antiviral; IncidènciaBackground & Aims Antiviral therapy may attenuate the risk of hepatocellular carcinoma (HCC) in patients with chronic hepatitis B (CHB). We aimed to explore how tenofovir alafenamide (TAF) and tenofovir disoproxil fumarate (TDF) affect HCC risk in patients with CHB. Methods The REACH-B, aMAP, and mPAGE-B models were utilized to assess HCC risk in patients with CHB from two global randomized-controlled trials evaluating the impact of TAF vs. TDF treatment. Standard incidence ratios (SIRs) were calculated using data from the REACH-B model as a ratio of observed HCC cases in the TAF- or TDF-treated patients vs. predicted HCC cases for untreated historical controls. Proportions of treated patients shifting aMAP and mPAGE-B risk categories between baseline and Week 240 were calculated. Results Of the 1,632 patients (TAF, n = 1,093; TDF, n = 539) followed for up to 300 weeks, 22 HCC cases developed. Those receiving TAF had an SIR that was lower compared to the SIR of individuals receiving TDF: 0.32 (p <0.001) vs. 0.56 (p = 0.06). In the general study population, individuals without cirrhosis at baseline had an SIR that was lower compared to the SIR of individuals with cirrhosis at baseline: 0.37 (p <0.001) vs. 0.58 (p = 0.15). Of the patients at low risk of HCC at baseline, the majority (97%) remained low risk by mPAGE-B and aMAP scoring at Week 240. Among those at medium or high risk at baseline, substantial portions shifted to a lower risk category by Week 240 (mPAGE-B: 22% and 42%; aMAP: 39% and 63%, respectively). Conclusions This evaluation provides evidence that treatment with TAF or TDF can reduce HCC risk in patients with CHB, particularly in patients without cirrhosis. Impact and implications Despite the substantial impact of HCC on long-term outcomes of patients with CHB, the differential risk of HCC development among those receiving treatment with TAF vs. TDF has not been well elucidated. Using three validated risk prediction models, we found that TAF is at least as effective as TDF in reducing HCC risk in patients with CHB. While TDF is well-studied in the context of HCC risk reduction, our novel findings underscore the effectiveness of TAF as a treatment option for patients with CHB. Clinical trial numbers NCT01940341; NCT02836249; NCT01940471; NCT02836236.This study was sponsored by Gilead Sciences. This article was based on the original studies GS-US-320-0108 and GS-US-320-0110 sponsored by Gilead Sciences. Support for third-party writing assistance for this article, provided by Julianna Catania, MPH, and Isabel Haber, BS, Costello Medical, US, was funded by Gilead in accordance with Good Publication Practice (GPP3) guidelines (http://www.ismpp.org/gpp3).ElsevierInstitut Català de la Salut[Lim YS] Asan Medical Center, University of Ulsan College of Medicine, Seoul, South Korea. [Chan HLY] The Chinese University of Hong Kong, Hong Kong. [Ahn SH] Yonsei University College of Medicine, Seoul, Republic of Korea. [Seto WK] University of Hong Kong, Hong Kong. [Ning Q] Tongji Hospital, Tongji Medical College, Wuhan, China. [Agarwal K] Institute of Liver Studies, Kings College Hospital, United Kingdom. [Buti M] Vall d’Hebron Hospital Universitari, Barcelona, Spain. CIBEREHD del Instituto Carlos III, Barcelona, SpainVall d'Hebron Barcelona Hospital Campus202320232023info:eu-repo/semantics/articleinfo:eu-repo/semantics/publishedVersionapplication/pdfapplication/pdfapplication/pdfhttps://hdl.handle.net/11351/10413http://hdl.handle.net/11351/10413Scientiareponame:Recercat. Dipósit de la Recerca de Catalunyainstname:Varias* (Consorci de Biblioteques Universitáries de Catalunya, Centre de Serveis Científics i Acadèmics de Catalunya)InglésJHEP Reports;5(10)https://doi.org/10.1016/j.jhepr.2023.100847Attribution-NonCommercial-NoDerivatives 4.0 Internationalhttp://creativecommons.org/licenses/by-nc-nd/4.0/info:eu-repo/semantics/openAccessoai:recercat.cat:11351/104132026-05-29T05:05:01Z
score 15.812429

Registros relacionados